Hyderabad News Desk

DelveInsight’s, “Myositis Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myositis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Myositis Pipeline Report

• DelveInsight’s Myositis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myositis treatment.
• The leading companies working in the Myositis Market include Corbus Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Promising Myositis Pipeline Therapies in the various stages of development include ABC008, Daxdilimab, BYM338 (Bimagrumab), EFG PH20 SC, Nipocalimab, Glucocorticoids, and others.
• September 2023: Pfizer announced a study of Phase 3 Clinical Trials for PF-06823859. The purpose of the study is to understand how the study medicine PF-06823859 works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM.
• September 2023: Janssen Research & Development LLC announced a study of Phase 2 Clinical trials for Nipocalimab and Glucocorticoids. The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM).

Request a sample and discover the recent advances in Myositis Treatment Drugs @ Myositis Pipeline Report

In the Myositis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Myositis Overview

The term “myositis” refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest. Other conditions that can cause muscle weakness and pain include infection, muscle injury from medications, inherited diseases, electrolyte imbalances, and thyroid disease.

Find out more about Myositis Therapeutics Assessment @ Myositis Preclinical and Discovery Stage Products

Myositis Emerging Drugs Profile

• Lenabasum: Corbus Pharmaceuticals
• Nipocalimab: Janssen Research & Development, LLC

Myositis Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the Myositis therapies. The Myositis companies which have their Myositis drug candidates in the most advanced stage, i.e. phase III include, Corbus Pharmaceuticals.

Learn more about the emerging Myositis Pipeline Therapies @ Myositis Clinical Trials Assessment

Scope of the Myositis Pipeline Report

• Coverage- Global
• Myositis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myositis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Myositis Companies- Corbus Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Myositis Pipeline Therapies- ABC008, Daxdilimab, BYM338 (Bimagrumab), EFG PH20 SC, Nipocalimab, Glucocorticoids, and others.

Dive deep into rich insights for new drugs for Myositis Treatment, Visit @ Myositis Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Myositis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myositis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Lenabasum: Corbus Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nipocalimab: Janssen Research & Development, LLC
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Myositis Key Companies
18. Myositis Key Products
19. Myositis- Unmet Needs
20. Myositis- Market Drivers and Barriers
21. Myositis- Future Perspectives and Conclusion
22. Myositis Analyst Views
23. Myositis Key Companies
24. Appendix

For further information on the Myositis Pipeline therapeutics, reach out to Myositis Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking